Emerging Concepts on the Pathogenesis of Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Fatty Liver Disease: A Practical Guide

Volumn , Issue , 2013, Pages 46-61

  Leclercq, Isabelle A ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Cryptogenic cirrhosis; Hepatocellular carcinoma (HCC); Metabolic control; Metabolic syndrome; Microvascular complications; Non alcoholic fatty liver (NAFLD); Type 2 diabetes

Indexed keywords

EID: 84886152945     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118556153.ch5     Document Type: Chapter

References (44)

1. Anderson N, Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev. 2008 Sep;60(3):311-57.
2. Stefan N, Kantartzis K, Haring HU. Causes and metabolic consequences of fatty liver. Endocr Rev. 2008 Dec;29(7):939-60.
3. Yilmaz Y, Ones T, Purnak T, et al. Association between the presence of brown adipose tissue and nonalcoholic fatty liver disease in adult humans. Aliment Pharmacol Ther. 2011 Aug;34(3):318-23.
4. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Ann Rev Physiol. 2010 Mar 17;72:219-46.
5. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Ann Rev Immunol. 2011 Apr 23;29:415-45.
6. Yki-Jarvinen H. Fat in the liver and insulin resistance. Ann Med. 2005;37(5):347-56.
7. Kumashiro N, Erion DM, Zhang D, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA. 2011 Sep 27;108(39):16381-5.
8. Chawla A, Nguyen KD, Goh YP. Macrophagemediated inflammation in metabolic disease. Nat Rev Immunol. 2011 Nov;11(11):738-49.
9. Lee YS, Li P, Huh JY, et al. Inflammation is necessary for long-term but not short-term high-fat dietinduced insulin resistance. Diabetes. 2011;6:24-4.
10. Lanthier N, Molendi-Coste O, Horsmans Y, van RN, Cani PD, Leclercq IA. Kupffer cell activation is a causal factor for hepatic insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2010 Jan;298(1) :G107-G116.
11. Wu JW, Wang SP, Alvarez F, et al. Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis. Hepatology. 2011 Jul;54(1):122-32.
12. Schwabe RF, Maher JJ. Lipids in liver disease: looking beyond steatosis. Gastroenterology. 2012 Jan;142(1): 8-11.
13. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology. 2008 Aug;48(2):670-8.
14. Fu S, Yang L, Li P, et al. Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature. 2011 May 26;473(7348):528-31.
15. Gregor MF, Yang L, Fabbrini E, et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes. 2009 Mar;58(3):693-700.
16. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004 Nov 2;101(44):15718-23.
17. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest. 2011 Jun;121(6): 2126-32.
18. Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacol Ther. 2011 May;130(2): 202-12.
19. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5. Science. 2010 Apr 9;328 (5975):228-31.
20. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012 Apr;142(4)711-25.
21. Leclercq IA, Da Silva MA, Schroyen B, Van HN, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol. 2007 Jul;47(1):142-56.
22. Fujita K, Nozaki Y, Wada K, et al. Dysfunctional verylow- density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology. 2009 Sep;50(3):772-80.
23. Lewis GF, Uffelman KD, Szeto LW, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes. 1993 Jun;42(6):833-42.
24. Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of nonobese Asian subjects. Atherosclerosis. 2009 Apr;203 (2):581-6.
25. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010 Nov;52(5):1836-46.
26. Yesilova Z, Yaman H, Oktenli C, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2005 Apr;100(4):850-5.
27. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011 Jun 24;332(6037):1519-23.
28. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008 Nov;295(5):G987-95.
29. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007 Oct;46(4):1081-90.
30. Caballero F, Fernandez A, De Lacy AM, Fernandez-Checa JC, Caballeria J, Garcia-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol. 2009 Apr;50(4):789-96.
31. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest. 2002 Oct;110(7):905-11.
32. Van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology. 2011 Oct;141(4):1393-403.
33. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011 Jul;54(1):133-44.
34. Moustafa T, Fickert P, Magnes C, et al. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology. 2012 Jan;142(1): 140-51.
35. Teratani T, Tomita K, Suzuki T, et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology. 2012 Jan;142(1):152-64.
36. Kim JY, van de Wall E, Laplante M, et al. Obesityassociated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007 Sep;117(9):2621-37.
37. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fattyliver disease: a systematic review and meta-analysis. Metabolism. 2011 Mar;60(3):313-26.
38. Wree A, Dechene A, Herzer K, et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84 (1):54-9.
39. Lanthier N, Horsmans Y, Leclercq IA. The metabolic syndrome: how it may influence hepatic stellate cell activation and hepatic fibrosis. Curr Opin Clin Nutr Metab Care. 2009 Jul;12(4):404-11.
40. Gao B, Jeong WI, Tian Z. Liver: an organ with predominant innate immunity. Hepatology. 2008 Feb; 47(2):729-36.
41. Brenner DA, Seki E, Taura K, et al. Non-alcoholic steatohepatitis-induced fibrosis: toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res. 2011 Jul;41(7):683-6.
42. Erridge C. Diet, commensals and the intestine as sources of pathogen-associated molecular patterns in atherosclerosis, type 2 diabetes and non-alcoholic fatty liver disease. Atherosclerosis. 2011 May;216(1): 1-6.
43. Miura K, Kodama Y, Inokuchi S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010 Jul;139(1):323-34.
44. Gao B. Innate immunity and steatohepatitis: a critical role of another toll (TLR-9). Gastroenterology. 2010 Jul;139(1):27-30.